Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Risk Guided Treatment of DLBCL
NCT00055640Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2002
- Primary completion
- Apr 2005
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Molecular risk assessment prediction of response. Started Oct 2002; status: completed.
02
Drugs
rituximabcyclophosphamidepegylated liposomal doxorubicinvincristine sulfate liposome injectionprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00055640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055640.